Goldman Sachs’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $46M | Sell |
349,179
-15,356
| -4% | -$2.04M | 0.01% | 1645 |
|
|
2025
Q4 | $51.7M | Sell |
364,535
-245,078
| -40% | -$35.5M | 0.01% | 1485 |
|
|
2025
Q3 | $85.6M | Sell |
609,613
-76,252
| -11% | -$10.3M | 0.01% | 1037 |
|
|
2025
Q2 | $86.2M | Sell |
685,865
-51,572
| -7% | -$5.91M | 0.01% | 979 |
|
|
2025
Q1 | $81.6M | Sell |
737,437
-246,362
| -25% | -$31.2M | 0.01% | 895 |
|
|
2024
Q4 | $134M | Sell |
983,799
-33,355
| -3% | -$4.13M | 0.02% | 662 |
|
|
2024
Q3 | $117M | Sell |
1,017,154
-115,435
| -10% | -$15.8M | 0.02% | 725 |
|
|
2024
Q2 | $156M | Buy |
1,132,589
+356,862
| +46% | +$48.9M | 0.03% | 594 |
|
|
2024
Q1 | $107M | Buy |
775,727
+84,095
| +12% | +$11.5M | 0.02% | 743 |
|
|
2023
Q4 | $91.1M | Sell |
691,632
-95,323
| -12% | -$11M | 0.02% | 837 |
|
|
2023
Q3 | $88.5M | Sell |
786,955
-37,682
| -5% | -$3.97M | 0.02% | 781 |
|
|
2023
Q2 | $77.8M | Sell |
824,637
-145,163
| -15% | -$14.2M | 0.02% | 832 |
|
|
2023
Q1 | $98.2M | Sell |
969,800
-359,922
| -27% | -$37.5M | 0.02% | 705 |
|
|
2022
Q4 | $159M | Buy |
1,329,722
+127,932
| +11% | +$15M | 0.04% | 504 |
|
|
2022
Q3 | $128M | Sell |
1,201,790
-53,033
| -4% | -$5.38M | 0.03% | 568 |
|
|
2022
Q2 | $122M | Sell |
1,254,823
-241,629
| -16% | -$22.3M | 0.03% | 594 |
|
|
2022
Q1 | $140M | Sell |
1,496,452
-28,063
| -2% | -$2.38M | 0.03% | 573 |
|
|
2021
Q4 | $130M | Buy |
1,524,515
+81,017
| +6% | +$7.45M | 0.03% | 659 |
|
|
2021
Q3 | $138M | Buy |
1,443,498
+20,210
| +1% | +$1.91M | 0.03% | 575 |
|
|
2021
Q2 | $139M | Buy |
1,423,288
+15,814
| +1% | +$1.52M | 0.03% | 553 |
|
|
2021
Q1 | $137M | Buy |
1,407,474
+189,709
| +16% | +$19.9M | 0.03% | 499 |
|
|
2020
Q4 | $117M | Buy |
1,217,765
+328,594
| +37% | +$31.7M | 0.03% | 538 |
|
|
2020
Q3 | $85.5M | Sell |
889,171
-55,498
| -6% | -$6.42M | 0.02% | 655 |
|
|
2020
Q2 | $115M | Buy |
944,669
+42,587
| +5% | +$4.71M | 0.04% | 497 |
|
|
2020
Q1 | $78.1M | Buy |
902,082
+242,342
| +37% | +$23.7M | 0.03% | 615 |
|
|
2019
Q4 | $70.9M | Sell |
659,740
-8,347
| -1% | -$874K | 0.02% | 914 |
|
|
2019
Q3 | $60.2M | Buy |
668,087
+95,698
| +17% | +$8.94M | 0.02% | 990 |
|
|
2019
Q2 | $48.3M | Buy |
572,389
+37,857
| +7% | +$3.11M | 0.01% | 1163 |
|
|
2019
Q1 | $47.1M | Sell |
534,532
-43,115
| -7% | -$3.6M | 0.01% | 1172 |
|
|
2018
Q4 | $41.3M | Sell |
577,647
-733,011
| -56% | -$70.2M | 0.01% | 1231 |
|
|
2018
Q3 | $161M | Sell |
1,310,658
-128,782
| -9% | -$14.6M | 0.04% | 492 |
|
|
2018
Q2 | $141M | Sell |
1,439,440
-341,934
| -19% | -$30.6M | 0.04% | 552 |
|
|
2018
Q1 | $148M | Sell |
1,781,374
-351,821
| -16% | -$29.7M | 0.04% | 573 |
|
|
2017
Q4 | $166M | Sell |
2,133,195
-305,162
| -13% | -$20.8M | 0.04% | 542 |
|
|
2017
Q3 | $149M | Sell |
2,438,357
-235,860
| -9% | -$12.4M | 0.04% | 570 |
|
|
2017
Q2 | $123M | Buy |
2,674,217
+930,268
| +53% | +$45.1M | 0.03% | 644 |
|
|
2017
Q1 | $75.5M | Buy |
1,743,949
+997,434
| +134% | +$42.7M | 0.02% | 942 |
|
|
2016
Q4 | $28.9M | Buy |
746,515
+24,619
| +3% | +$1.11M | 0.01% | 1685 |
|
|
2016
Q3 | $36.6M | Buy |
721,896
+81,257
| +13% | +$4.05M | 0.01% | 1445 |
|
|
2016
Q2 | $29.1M | Sell |
640,639
-142,600
| -18% | -$6.57M | 0.01% | 1510 |
|
|
2016
Q1 | $31M | Buy |
783,239
+574,102
| +275% | +$22.8M | 0.01% | 1403 |
|
|
2015
Q4 | $11.8M | Sell |
209,137
-112,837
| -35% | -$5.73M | ﹤0.01% | 2124 |
|
|
2015
Q3 | $12.8M | Buy |
321,974
+87,128
| +37% | +$4.21M | ﹤0.01% | 2051 |
|
|
2015
Q2 | $11.2M | Sell |
234,846
-333,762
| -59% | -$14.2M | ﹤0.01% | 2244 |
|
|
2015
Q1 | $22.6M | Buy |
568,608
+154,995
| +37% | +$5.54M | 0.01% | 1668 |
|
|
2014
Q4 | $9.24M | Sell |
413,613
-203,819
| -33% | -$3.86M | ﹤0.01% | 2410 |
|
|
2014
Q3 | $9.68M | Sell |
617,432
-4,647
| -0.7% | -$69.5K | ﹤0.01% | 2391 |
|
|
2014
Q2 | $9.23M | Sell |
622,079
-119,491
| -16% | -$1.69M | ﹤0.01% | 2431 |
|
|
2014
Q1 | $11.9M | Buy |
741,570
+321,720
| +77% | +$5.5M | ﹤0.01% | 2214 |
|
|
2013
Q4 | $3.92M | Sell |
419,850
-120,142
| -22% | -$1.17M | ﹤0.01% | 3356 |
|
|
2013
Q3 | $6.11M | Buy |
539,992
+187,314
| +53% | +$2.57M | ﹤0.01% | 2731 |
|
|
2013
Q2 | $4.72M | Buy |
+352,678
| New | +$4.33M | ﹤0.01% | 2806 |
|
Other funds holding NBIX
VPM
VCM
Goldman Sachs's NBIX Position: Q1 2026 in Review
Goldman Sachs reduced its Neurocrine Biosciences (NBIX) stake by 4.2% in Q1 2026, selling an estimated $2.04M and leaving 349,179 shares worth $46M. The position accounts for 0.01% of the portfolio, ranked #1645.
Goldman Sachs first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $166M in Q4 2017. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Goldman Sachs held 349,179 shares of Neurocrine Biosciences worth $46M as of Q1 2026.
- Goldman Sachs sold 15,356 Neurocrine Biosciences shares in Q1 2026, an estimated $2.04M.
- Neurocrine Biosciences made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1645 holding.
- Goldman Sachs first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Neurocrine Biosciences position peaked at $166M in Q4 2017.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.